Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02796352 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study
A Phase 2 study, sponsored by Ahmad Tarhini.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02796352 is a Phase 2 study that was terminated before completion, run by Ahmad Tarhini. The registered enrollment target is 1 participants.
The verdict
NCT02796352, a Phase 2 study, was terminated before completion, sponsored by Ahmad Tarhini.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study is for patients with advanced stage III or stage IV melanoma not adequately treated by surgery who have progressed after treatment with nivolumab or pembrolizumab. The purpose of this study is to see if giving high dose interleukin-2 (IL-2) after progression on nivolumab or pembrolizumab is effective in treating metastatic melanoma. This study is also being done to look at the severity of side effects of IL-2 in patients. IL-2 is approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced melanoma.
Interventions
- DRUG High dose bolus interleukin-2 (HD IL2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-09 |
| Est. Completion | 2017-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02796352
The ClinicalTrials.gov registry entry for NCT02796352 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ahmad Tarhini, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which High dose bolus interleukin-2 (HD IL2) is the first listed.
NCT02796352 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02796352 about?
NCT02796352 is a clinical study titled "A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study". This study is for patients with advanced stage III or stage IV melanoma not adequately treated by surgery who have progressed after treatment with nivolumab or pembrolizumab. The purpose of this study is to see if giving high dose interleukin-2 (IL-2) after progression on nivolumab or pembrolizumab ...
What is the current status of trial NCT02796352?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2016-09. Estimated completion is 2017-04.
What interventions are being tested in trial NCT02796352?
The interventions under investigation include: High dose bolus interleukin-2 (HD IL2) (DRUG).
Who is sponsoring clinical trial NCT02796352?
This trial is sponsored by Ahmad Tarhini, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.